マイクロバイオーム治療薬の市場規模・予測、種類・用途・エンドユーザー・地域別の世界・地域シェア、動向、成長機会分析

マイクロバイオーム治療薬市場は、2022年の3億7,592万米ドルから2030年には8億1,338万米ドルに成長すると予測されており、2022年から2030年までのCAGRは10.1%を記録すると予測されています。

ヒトマイクロバイオームには、人体およびその周辺で確認されるすべての微生物とその関連代謝産物／産物が含まれます。技術の進歩により、健康や病気の維持におけるヒト腸内マイクロバイオームの多面的効果を調べることが可能になっています。ヒトの健康における微生物の広範な可能性により、微生物は疾病管理のための治療薬として使用される莫大な可能性を秘めています。マイクロバイオーム療法は、あらゆる重篤な病態を治療するための大きな可能性を秘めており、あらゆる環境における対人的な変動性や安定性といった重要な問題を克服することで、個別化治療の目的を達成するための潜在的な供給源として機能します。糞便微生物叢移植（FMT）やプロバイオティクスのような、外因性微生物の投与に依存する戦略は、ディスバイオーシスに関連する疾患を管理するために使用される可能性があります。

ヒトの健康維持における腸内細菌叢の可能性がマイクロバイオーム治療薬市場の成長を促す

マイクロバイオーム治療薬は、バクテリオファージ、バクテリオシン、抗生物質、常在細菌または合成細菌、あるいは減算的治療または調節的治療を用いて腸内マイクロバイオームを改変することを目的としています。個別化、調和化、信頼性、持続性のある治療を提供することで、この戦略は従来の治療法の限界を克服することができます。世界の治療薬市場は、その莫大な経済的可能性を示しています。研究では、炎症性腸疾患、肥満、さらには精神疾患などの疾患に対するマイクロバイオーム治療薬の使用で有望な結果が示されています。現在進行中の調査では、がん治療、糖尿病管理、心臓血管の健康といった分野におけるマイクロバイオームに基づく介入の可能性も模索されています。さらに、消化器疾患の罹患率は年齢とともに増加し、2021年2月のGIアライアンスのデータでは、約2,000万人の米国人が慢性消化器疾患を患っており、毎年6,200万人以上の米国人が消化器疾患の診断を受けていると推定されています。国際胃腸障害財団（IFFGD）は、GERD有病率は北米で18％～28％、南米で23％、欧州で9～26％という統計を発表しました。従って、今後数年間は、胃腸障害の頻度の増加が市場拡大の原動力となると思われます。

マイクロバイオームと疾患発症の複雑な関係を理解することで、科学者たちは単に症状を管理するのではなく、問題の根本原因をターゲットにした個別化治療を開発しています。知識の拡大と技術の進歩に伴い、マイクロバイオーム治療薬は現代医学の礎となる可能性を秘めており、さまざまな疾患に罹患している人々の健康状態の改善に希望をもたらします。

ヒトの健康と疾患におけるマイクロバイオームの重要性が認識されるようになったことで、ヒトのマイクロバイオームをさらに理解し、マイクロバイオーム治療薬を開発するための厳格な研究開発が奨励されるようになっています。その結果、潜在的な治療薬の開発や阻害要因の特定に役立っています。技術や研究ツールの進歩も、研究開発の発展に寄与しています。次世代シーケンサーとメタゲノム解析により、マイクロバイオームのより包括的で詳細な研究が可能になっています。これらのツールにより、研究者は特定の微生物種とその機能を特定し、マイクロバイオームの経時的変化を追跡できるようになっています。FDAのような規制当局も、マイクロバイオーム治療薬の分野における研究開発努力を支援しています。FDAはFMTのガイドラインを制定し、安全性と有効性を確保するための規制経路を通じてこの分野を前進させることに関心を寄せています。規制当局からのこのような支援は、企業がマイクロバイオーム治療薬を開発・試験するための枠組みを提供し、投資家にこれらの治療法の成功の可能性を確信させます。全体として、マイクロバイオーム治療薬への関心の高まりと資金調達は、研究開発の推進力となっています。これにより、ヒトのマイクロバイオームに対する理解が深まり、マイクロバイオームを調節してヒトの健康を改善できる標的治療薬の開発が進むことになります。

マイクロバイオーム治療薬市場は、種類、用途、エンドユーザー、地域によって分けられます。マイクロバイオーム治療薬市場は、タイプ、アプリケーション、エンドユーザーに基づいて分割されます。タイプ別では、マイクロバイオーム治療薬市場は治療薬と処置に区分されます。用途別では、マイクロバイオーム治療薬市場は、代謝障害および肥満、C. difficile感染症、炎症性腸疾患に区分されます。エンドユーザー別では、マイクロバイオーム治療薬市場は病院・クリニック、外来手術センター、在宅医療に分類されます。

地域別に見ると、市場は北米、欧州、アジア太平洋、中東・アフリカ、中南米に区分されます。マイクロバイオーム治療薬市場では、北米が最大の市場シェアを占めています。北米は、ジフィシル感染症患者の増加、技術の進歩、腸内細菌叢の重要性に対する意識の高まりにより、大きな市場シェアを占めています。健康維持と疾病予防におけるヒトマイクロバイオームの重要性に対する理解が深まったことで、米国の研究者はマイクロバイオームに基づく介入を様々な病態の治療に有望なアプローチとして模索するようになっています。さらに、肥満や炎症性腸疾患などの慢性疾患の有病率が上昇していることから、革新的な治療法に対する需要が高まり、マイクロバイオーム治療薬の開発に拍車がかかっています。遺伝子配列決定とバイオインフォマティクスの技術的進歩はマイクロバイオームの研究と改変を可能にし、個別化されたマイクロバイオームに基づく介入の開発を促進します。個別化医療の動向は、オーダーメイドのマイクロバイオーム治療薬とよく合致しています。学術界、産業界、政府機関の連携も研究開発に拍車をかけ、科学的発見の商業製品への転換を加速させています。規制当局がマイクロバイオーム治療薬の可能性を認識し、その開発と承認のためのガイダンスを提供しているため、この分野に対する規制当局の支援と投資は市場の成長にさらに貢献しています。

調査と技術革新に重点を置くことで、腸内細菌叢が健康に及ぼす影響について大きな理解が得られ、マイクロバイオーム治療薬の確固たる基盤が築かれています。カナダではバイオテクノロジーと医薬品を支援する規制環境が整っているため、マイクロバイオームに焦点を当てた研究開発に投資する企業が増えています。さらに、ベンチャーキャピタルへの投資や政府からの資金提供の増加も、この研究に資本を注入しています。2020年1月、カナダ政府はパートナーとともに、重要なマイクロバイオーム研究に1,800万米ドルを投資しました。

全体的な健康状態における腸の健康とマイクロバイオームの重要性に対するカナダ国民の意識の高まりは、マイクロバイオームベースの製品に対する消費者の需要に拍車をかけています。さらに、カナダ・マイクロバイオーム・イニシアチブ（CMI）のような取り組みが広く実施されているため、カナダではパートナーや利害関係者との協力が容易になっています。そのため、マイクロバイオーム療法の開発に研究努力を集中させることが可能になっています。学術機関、バイオテクノロジー企業、ヘルスケア機関の連携や提携により、研究開発の取り組みが加速しています。さらに、カナダの企業は国際市場を開拓し、マイクロバイオーム治療薬の裾野を広げています。これらすべての要因が相まって、カナダにおけるマイクロバイオーム治療薬の有望な軌道が示されています。

ClinicalTrails.com、疾病管理予防センター（CDC）、食品医薬品局（FDA）は、マイクロバイオーム治療薬市場に関するレポート作成時に参照した一次情報および二次情報の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 マイクロバイオーム治療薬市場情勢

• PEST分析
  • 世界のPEST分析

第5章 マイクロバイオーム治療薬市場：主要な産業力学

• 市場促進要因
  • ヒトの健康維持における腸内細菌叢の可能性
  • マイクロバイオーム探索パイプラインを改善するための資金流入
• 市場抑制要因
  • 開発・生産コストの高さ
• 市場機会
  • ヒトマイクロバイオームの理解を深めるための研究開発の増加
• 今後の動向
  • ヒトマイクロバイオーム治療薬の技術的進歩
• インパクト分析

第6章 マイクロバイオーム治療薬市場：世界市場の分析

• マイクロバイオーム治療薬市場の収益、2020年～2030年

第7章 世界のマイクロバイオーム治療薬市場：収益と予測、タイプ別 (2030年まで)

• マイクロバイオーム治療薬市場の収益シェア：タイプ別 (%、2022年・2030年)
• 処置
• 治療薬

第8章 世界のマイクロバイオーム治療薬市場：収益と予測、用途別 (2030年まで)

• マイクロバイオーム治療薬市場の収益シェア：用途別 (%、2022年・2030年)
• 代謝異常と肥満
• ジフィシル感染症（CDI）
• 炎症性腸疾患
• その他

第9章 世界のマイクロバイオーム治療薬市場：収益と予測、エンドユーザー別 (2030年まで)

• マイクロバイオーム治療薬市場の収益シェア：エンドユーザー別 (%、2022年・2030年)
• 病院・診療所
• 外来手術センター
• 在宅医療
• その他

第10章 マイクロバイオーム治療薬市場：地域別分析

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • UAE
  • その他中東・アフリカ
• 中南米
  • ブラジル
  • アルゼンチン
  • その他中南米

第11章 マイクロバイオーム治療薬市場：業界情勢

• マイクロバイオーム治療薬市場の成長戦略
• 無機的成長戦略
• 有機的成長戦略

第12章 企業プロファイル

• Enterome
• Finch Therapeutics Group Inc
• Caelus Health
• Ferring Pharmaceuticals
• Pendulum Therapeutics INC
• AOBiome
• Seres Therapeutics
• Vedanta Biosciences
• COST-BRY Pty Ltd（BiomeBank）
• YSOPIA Bioscience

第13章 付録

List Of Tables

• Table 1. Microbiome Therapeutics Market Segmentation
• Table 2. Global Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 3. North America Microbiome Therapeutics Market, by Type- Revenue and Forecast to 2030 (US$ Million)
• Table 4. North America Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 5. North America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 6. North America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 7. US Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 8. US Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 9. US Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 10. US Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 11. Canada Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 12. Canada Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 13. Canada Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 14. Canada Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 15. Mexico Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 16. Mexico Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 17. Mexico Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 18. Mexico Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 19. Europe Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 20. Europe Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 21. Europe Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 22. Europe Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 23. UK Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 24. UK Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 25. UK Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 26. UK Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 27. Germany Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 28. Germany Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 29. Germany Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 30. Germany Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 31. France Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 32. France Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 33. France Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 34. France Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 35. Italy Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 36. Italy Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 37. Italy Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 38. Italy Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 39. Spain Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 40. Spain Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 41. Spain Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 42. Spain Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 43. Rest of Europe Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 48. Rest of Europe Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
• Table 49. Rest of Europe Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
• Table 50. Rest of Europe Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
• Table 51. Asia Pacific Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 52. Asia Pacific Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 53. Asia Pacific Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 54. Asia Pacific Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 55. China Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 56. China Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 57. China Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 58. China Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 59. Japan Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 60. Japan Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 61. Japan Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 62. Japan Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 63. India Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 64. India Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 65. India Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 66. India Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 67. Australia Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 68. Australia Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 69. Australia Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 70. Australia Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 71. South Korea Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 72. South Korea Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 73. South Korea Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 74. South Korea Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 75. Rest of Asia Pacific Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 108. Rest of Asia Pacific Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 109. Rest of Asia Pacific Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 110. Rest of Asia Pacific Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 111. Middle East & Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 112. Middle East & Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 113. Middle East & Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 114. Middle East & Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 115. Saudi Arabia Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 116. Saudi Arabia Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 117. Saudi Arabia Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 118. Saudi Arabia Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 119. South Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 120. South Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 121. South Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 122. South Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 123. UAE Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 124. UAE Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 125. UAE Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 126. UAE Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 127. Rest of Middle East Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 128. Rest of Middle East Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 129. Rest of Middle East Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 130. Rest of Middle East Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 131. South & Central America Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 132. South & Central America Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 133. South & Central America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 134. South & Central America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 135. Brazil Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 136. Brazil Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 137. Brazil Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 138. Brazil Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 139. Argentina Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 140. Argentina Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 141. Argentina Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 142. Argentina Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 143. Rest of South & Central America Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 144. Rest of South & Central America Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
• Table 145. Rest of South & Central America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
• Table 146. Rest of South & Central America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 147. Recent Inorganic Growth Strategies in the Microbiome Therapeutics Market
• Table 148. Recent Organic Growth Strategies in Microbiome Therapeutics Market
• Table 149. Glossary of Terms, Microbiome Therapeutics Market

List Of Figures

• Figure 1. Microbiome Therapeutics Market Segmentation, By Geography
• Figure 2. Global - PEST Analysis
• Figure 3. Microbiome Therapeutics Market - Key Industry Dynamics
• Figure 4. Impact Analysis of Drivers and Restraints
• Figure 5. Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030
• Figure 6. Microbiome Therapeutics Market Revenue, Geography (US$ Mn), 2022 - 2030
• Figure 7. Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
• Figure 8. Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 9. Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 10. Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
• Figure 11. Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 12. C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 13. Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 14. Otehrs: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 15. Microbiome Therapeutics Market Revenue Share, End User, 2022 & 2030 (%)
• Figure 16. Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 17. Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 18. Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 19. Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 20. North America: Microbiome Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
• Figure 21. North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 22. North America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
• Figure 23. US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 24. Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 25. Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 26. Europe Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
• Figure 27. Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 28. Europe Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
• Figure 29. UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 30. Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 31. France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 32. Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 33. Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 34. Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 36. Asia Pacific Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
• Figure 37. Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 38. Asia Pacific Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
• Figure 39. China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 40. Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 41. India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 42. Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 43. South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 44. Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 53. Middle East & Africa Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
• Figure 54. Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 55. Middle East & Africa Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
• Figure 56. Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 57. South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 58. UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 59. Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 60. South & Central America Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
• Figure 61. South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 62. South & Central America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
• Figure 63. Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 64. Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 65. Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
• Figure 66. Growth Strategies in Microbiome Therapeutics Market

The microbiome therapeutics market is expected to grow from US$ 375.92 million in 2022 to US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030.

The human microbiome includes all the microorganisms and their related metabolites/products identified in and around the human body. Technological advancement has enabled the examination of the pleiotropic effects of the human gut microbiome in maintaining health and diseases. With the extensive potential of microbes in human health, they hold enormous potential to be used as therapeutics for disease management. Microbiome therapy holds great promise to treat any severe type of disease condition and acts as the potential source to achieve the objective of personalized therapy by overcoming key issues like interpersonal variability and stability in every type of environment. Strategies such as fecal microbiota transplantation (FMT) or probiotics that rely on the administration of exogenous microbes could be used to manage dysbiosis-related disorders.

Potential of Gut Microbiota in Maintaining Human Health drives the growth the Microbiome Therapeutics Market

Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) released statistics showing that GERD prevalence ranges from 18% to 28% in North America, 23% in South America, and 9-26% in Europe. Therefore, in the upcoming years, the increasing frequency of gastrointestinal disorders will fuel the market expansion.

By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.

The growing recognition of the microbiome's importance in human health and disease has encouraged rigorous research and development efforts to further understand the human microbiome and develop microbiome therapeutics. It has helped develop potential therapeutics and identify hindrances. Advancements in technology and research tools have also contributed to growing R&D. Next-generation sequencing and metagenomic analysis have allowed for a more comprehensive and detailed study of the microbiome. These tools enable researchers to identify specific microbial species and their functions, as well as track changes in the microbiome over time. Regulatory agencies, such as the FDA, are also supporting R&D efforts in the field of microbiome therapeutics. The FDA has established guidelines for FMT and has developed interest in advancing the field through regulatory pathways to ensure safety and efficacy. This support from regulatory agencies provides a framework for companies to develop and test microbiome-based therapies, giving investors confidence in the potential success of these treatments. Overall, the increased interest and funding in microbiome therapeutics are driving more research and development efforts. This will lead to a better understanding of the human microbiome and the development of targeted therapies that can modulate the microbiome to improve human health.

The microbiome therapeutics market is divided on the basis of type, application, end user, and geography. The microbiome therapeutics market is divided on the basis of type, application, and end user. Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. By application, the microbiome therapeutics market is segmented into metabolic disorders and obesity, C. difficile infection, and inflammatory bowel diseases. In terms of end users, the microbiome therapeutics market is classified as hospitals and clinics, ambulatory surgery centers, and home care.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the microbiome therapeutics market. North America accounts for a significant market share owing to the growing incidences of C. difficile cases, technological advances, and growing awareness about the importance of gut microbiota. The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treat various conditions. Additionally, the dominance of this country in the microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

An emphasis on research and innovation has yielded a significant understanding of the impact of gut microbiota on health, providing a solid foundation for microbiome-based therapeutics. A supportive regulatory environment for biotechnology and pharmaceuticals in Canada has encouraged companies to invest in microbiome-focused research and development. Additionally, increased venture capital investments and government funding have infused capital into this research. In January 2020, the Government of Canada, along with its partners, invested US$ 18 million in crucial microbiome research.

The rising awareness among Canadians about the importance of gut health and microbiome in overall well-being has spurred consumer demand for microbiome-based products. Moreover, the widespread implementation of initiatives such as the Canadian Microbiome Initiative (CMI) makes working with partners and stakeholders easier in Canada. This makes it possible to concentrate research efforts on the development of microbiome therapies. Collaborations and partnerships between academic institutions, biotechnology firms, and healthcare organizations have accelerated research and development efforts. Moreover, Canadian companies are exploring international markets, expanding the reach of microbiome therapeutics. All these factors combined indicate a promising trajectory for microbiome therapeutics in Canada.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the microbiome therapeutics market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the microbiome therapeutics market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Microbiome Therapeutics Market, by Geography

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Microbiome Therapeutics Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
  • 4.2.1 Global PEST Analysis

5. Microbiome Therapeutics Market - Key Industry Dynamics

• 5.1 Market Drivers:
  • 5.1.1 Potential of Gut Microbiota in Maintaining Human Health
  • 5.1.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
• 5.2 Market Restraints
  • 5.2.1 High Cost of Development and Production
• 5.3 Market Opportunities
  • 5.3.1 Increasing R&D to Gain Better Understanding of Human Microbiome
• 5.4 Future Trends
  • 5.4.1 Technological Advancement in Human Microbiome Therapeutics
• 5.5 Impact Analysis:

6. Microbiome Therapeutics Market - Global Market Analysis

• 6.1 Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030

7. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Type

• 7.1 Overview
• 7.2 Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
• 7.3 Procedure
  • 7.3.1 Overview
  • 7.3.2 Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Therapeutics
  • 7.4.1 Overview
  • 7.4.2 Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.2.1 Global: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)

8. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Application

• 8.1 Overview
• 8.2 Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
• 8.3 Metabolic Disorder and Obesity
  • 8.3.1 Overview
  • 8.3.2 Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 C. Difficile Infection (CDI)
  • 8.4.1 Overview
  • 8.4.2 C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Inflammatory Bowel Disease
  • 8.5.1 Overview
  • 8.5.2 Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 8.6 Others
  • 8.6.1 Overview
  • 8.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by End User

• 9.1 Overview
• 9.2 Microbiome Therapeutics Market Revenue Share, by End User, 2022 & 2030 (%)
• 9.3 Hospitals and Clinics
  • 9.3.1 Overview
  • 9.3.2 Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 9.4 Ambulatory Surgical Centers
  • 9.4.1 Overview
  • 9.4.2 Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 9.5 Homecare
  • 9.5.1 Overview
  • 9.5.2 Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
• 9.6 Others
  • 9.6.1 Overview
  • 9.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Microbiome Therapeutics Market - Geographical Analysis

• 10.1 North America Microbiome Therapeutics Market, Revenue and Forecast To 2030
  • 10.1.1 Overview
  • 10.1.2 North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • 10.1.3 North America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    • 10.1.3.1 North America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
  • 10.1.4 North America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
  • 10.1.5 North America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.1.6 North America Microbiome Therapeutics Market, by Country
    • 10.1.6.1 US
      • 10.1.6.1.1 Overview
      • 10.1.6.1.2 US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.1.6.1.3 US: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.1.6.1.3.1 US: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.1.6.1.4 US: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.1.6.1.5 US: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.1.6.2 Canada
      • 10.1.6.2.1 Overview
      • 10.1.6.2.2 Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.1.6.2.3 Canada: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.1.6.2.3.1 Canada: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.1.6.2.4 Canada: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.1.6.2.5 Canada: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.1.6.3 Mexico
      • 10.1.6.3.1 Overview
      • 10.1.6.3.2 Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.1.6.3.3 Mexico: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.1.6.3.3.1 Mexico: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.1.6.3.4 Mexico: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.1.6.3.5 Mexico: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
• 10.2 Europe Microbiome Therapeutics Market, Revenue and Forecast to 2030
  • 10.2.1 Overview
  • 10.2.2 Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • 10.2.3 Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    • 10.2.3.1 Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
  • 10.2.4 Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
  • 10.2.5 Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.2.6 Europe Microbiome Therapeutics Market, by Country
    • 10.2.6.1 UK
      • 10.2.6.1.1 Overview
      • 10.2.6.1.2 UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.2.6.1.3 UK: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.6.1.3.1 UK: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.2.6.1.4 UK: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.2.6.1.5 UK: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6.2 Germany
      • 10.2.6.2.1 Overview
      • 10.2.6.2.2 Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.2.6.2.3 Germany: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.6.2.3.1 Germany: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.2.6.2.4 Germany: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.2.6.2.5 Germany: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6.3 France
      • 10.2.6.3.1 Overview
      • 10.2.6.3.2 France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.2.6.3.3 France: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.6.3.3.1 France: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.2.6.3.4 France: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.2.6.3.5 France: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6.4 Italy
      • 10.2.6.4.1 Overview
      • 10.2.6.4.2 Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.2.6.4.3 Italy: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.6.4.3.1 Italy: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.2.6.4.4 Italy: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.2.6.4.5 Italy: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6.5 Spain
      • 10.2.6.5.1 Overview
      • 10.2.6.5.2 Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.2.6.5.3 Spain: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.6.5.3.1 Spain: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.2.6.5.4 Spain: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.2.6.5.5 Spain: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6.7 Rest of Europe
      • 10.2.6.7.1 Overview
      • 10.2.6.7.2 Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.2.6.7.3 Rest of Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.6.7.3.1 Rest of Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.2.6.7.4 Rest of Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.2.6.7.5 Rest of Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
• 10.3 Asia Pacific Microbiome Therapeutics Market, Revenue and Forecast to 2030
  • 10.3.1 Overview
  • 10.3.2 Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • 10.3.3 Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    • 10.3.3.1 Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
  • 10.3.4 Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
  • 10.3.5 Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.3.6 Asia Pacific Microbiome Therapeutics Market, by Country
    • 10.3.6.1 China
      • 10.3.6.1.1 Overview
      • 10.3.6.1.2 China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.3.6.1.3 China: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.6.1.3.1 China: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.3.6.1.4 China: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.3.6.1.5 China: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6.2 Japan
      • 10.3.6.2.1 Overview
      • 10.3.6.2.2 Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.3.6.2.3 Japan: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.6.2.3.1 Japan: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.3.6.2.4 Japan: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.3.6.2.5 Japan: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6.3 India
      • 10.3.6.3.1 Overview
      • 10.3.6.3.2 India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.3.6.3.3 India: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.6.3.3.1 India: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.3.6.3.4 India: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.3.6.3.5 India: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6.4 Australia
      • 10.3.6.4.1 Overview
      • 10.3.6.4.2 Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.3.6.4.3 Australia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.6.4.3.1 Australia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.3.6.4.4 Australia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.3.6.4.5 Australia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6.5 South Korea
      • 10.3.6.5.1 Overview
      • 10.3.6.5.2 South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.3.6.5.3 South Korea: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.6.5.3.1 South Korea: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.3.6.5.4 South Korea: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.3.6.5.5 South Korea: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6.7 Rest of Asia Pacific
      • 10.3.6.7.1 Overview
      • 10.3.6.7.2 Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.3.6.7.3 Rest of Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.6.7.3.1 Rest of Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.3.6.7.4 Rest of Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.3.6.7.5 Rest of Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
• 10.4 Middle East & Africa Microbiome Therapeutics Market, Revenue and Forecast to 2030
  • 10.4.1 Overview
  • 10.4.2 Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • 10.4.3 Middle East & Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    • 10.4.3.1 Middle East & Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
  • 10.4.4 Middle East & Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
  • 10.4.5 Middle East & Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.4.5.1 Middle East & Africa Microbiome Therapeutics Market, by Country
    • 10.4.5.2 Saudi Arabia
      • 10.4.5.2.1 Overview
      • 10.4.5.2.2 Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.4.5.2.3 Saudi Arabia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.4.5.2.3.1 Saudi Arabia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.4.5.2.4 Saudi Arabia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.4.5.2.5 Saudi Arabia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.4.5.3 South Africa
      • 10.4.5.3.1 Overview
      • 10.4.5.3.2 South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.4.5.3.3 South Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.4.5.3.3.1 South Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.4.5.3.4 South Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.4.5.3.5 South Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.4.5.4 UAE
      • 10.4.5.4.1 Overview
      • 10.4.5.4.2 UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.4.5.4.3 UAE: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.4.5.4.3.1 UAE: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.4.5.4.4 UAE: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.4.5.4.5 UAE: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.4.5.5 Rest of Middle East Africa
      • 10.4.5.5.1 Overview
      • 10.4.5.5.2 Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.4.5.5.3 Rest of Middle East Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.4.5.5.3.1 Rest of Middle East Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.4.5.5.4 Rest of Middle East Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.4.5.5.5 Rest of Middle East Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
• 10.5 South & Central America Microbiome Therapeutics Market, Revenue and Forecast to 2030
  • 10.5.1 Overview
  • 10.5.2 South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • 10.5.3 South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    • 10.5.3.1 South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
  • 10.5.4 South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
  • 10.5.5 South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.5.6 South & Central America Microbiome Therapeutics Market, by Country
    • 10.5.6.1 Brazil
      • 10.5.6.1.1 Overview
      • 10.5.6.1.2 Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.5.6.1.3 Brazil: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.5.6.1.3.1 Brazil: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.5.6.1.4 Brazil: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.5.6.1.5 Brazil: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.5.6.2 Argentina
      • 10.5.6.2.1 Overview
      • 10.5.6.2.2 Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.5.6.2.3 Argentina: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.5.6.2.3.1 Argentina: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.5.6.2.4 Argentina: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.5.6.2.5 Argentina: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.5.6.3 Rest of South & Central America
      • 10.5.6.3.1 Overview
      • 10.5.6.3.2 Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.5.6.3.3 Rest of South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.5.6.3.3.1 Rest of South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
      • 10.5.6.3.4 Rest of South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
      • 10.5.6.3.5 Rest of South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)

11. Microbiome Therapeutics Market - Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Microbiome Therapeutics Market
• 11.3 Inorganic Growth Strategies
  • 11.3.1 Overview
• 11.4 Organic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Enterome
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Finch Therapeutics Group Inc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Caelus Health
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Ferring Pharmaceuticals
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Pendulum Therapeutics INC
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 AOBiome
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Seres Therapeutics
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 Vedanta Biosciences
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 COST-BRY Pty Ltd (BiomeBank)
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 YSOPIA Bioscience
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments

13. Appendix

• 13.1 About Us
• 13.2 Glossary of Terms